What does this company do and how does it make money?

Insmed operates a concentrated rare disease business model with exceptional pricing power but limited diversification. The company's two-product portfolio commands premium pricing typical of orphan drugs, yet remains entirely dependent on respiratory disease markets with three-quarters of revenue from the U.S. healthcare system.

Five legendary investment frameworks analyzed this company.

Lynch sees a turnaround at 85.4% growth while Graham sees speculation at -28.3x earnings — but both miss why insiders flee what institutions embrace at a 209.7% premium to value. Tap any framework below to explore their complete analysis and discover which lens best matches your investment philosophy.

How much cash does it generate and where does it go?

Insmed consumes cash at an accelerating pace even as revenue surges, burning nearly a dollar for every dollar of revenue generated. The elimination of stock-based compensation suggests either supreme confidence or cash preservation mode, while the $1.4B cash cushion provides a finite runway to reach profitability.

Is the business getting stronger or weaker?

The business shows dramatic operational improvement across every metric except the one that matters most — profitability. While margins expand and revenue accelerates, the low operating leverage means each dollar of growth costs $2.70 in operating expense, creating a widening gap between operational progress and financial sustainability.

What could go wrong and has it survived trouble before?

Insmed faces extreme concentration risk with its entire business dependent on two rare disease drugs in a single therapeutic area. The seven-quarter insider selling streak suggests those closest to the business see heightened risk, while the company's sensitivity to market stress reveals operational fragility beneath the growth story.

When gross margins hit 82.5% but you still lose $328M, the problem is not pricing — it is scale.

Is the stock priced for perfection, fair value, or pessimism?

The market prices Insmed for a transformation that traditional valuation models cannot capture, with the stock trading at more than triple its DCF value. The extreme earnings reaction asymmetry and universal analyst optimism suggest investors have positioned for flawless execution, leaving little room for disappointment despite the company's history of burning $1.28B annually.